Table 2.
Patient clinical characteristics.
| Clinical features | ||
|---|---|---|
| BMI | 32.6 (13.6) | |
| History of smoking/tobacco use; n = 20 | 10 (50%) | |
| Pregnant | 1 (5%) | |
| SOFA score on admission | 1 (2) | |
| Days in hospital | 11 (17) | |
| Died in hospital | 3 (14%) | |
| Received blood transfusion during stay | 5 (24%) | |
| Units received | 4 (16) | |
| Use of anticoagulants prior to admission | 3 (14%) | |
| Aspirin | 2 (10%) | |
| Rivaroxaban | 1 (5%) | |
| Received anticoagulants in hospital | 19 (91%) | |
| Apixaban | 3 (14%) | |
| Aspirin | 2 (10%) | |
| Enoxaparin sodium | 10 (48%) | |
| Heparin | 5 (24%) | |
| Rivaroxaban | 1 (5%) | |
| Use of immunosuppressants (for transplant) | 3 (14%) | |
| Patient labs on admission | Research subjects | Reference range |
|---|---|---|
| Hematology | ||
|
RBCs (106/µL) n = 21 |
4.40 (0.68) |
M: 4.0–5.7 F: 3.9–5.1 |
|
WBCs (103/µL) n = 20 |
9.7 (6.2) | 4.5–11.0 |
|
Platelets (103/µL) n = 20 |
226 (123) | 153–367 |
|
Hemoglobin (g/dL) n = 20 |
12.4 (3.8) |
M: 12.6–17.4 F: 11.9–15.7 |
|
Hematocrit (%) n = 20 |
37.8 (10.2) |
M: 37–50 F: 35–45 |
|
MCV (fL) n = 19 |
89.8 (8.2) | 80–96 |
|
MCHC (g/dL) n = 19 |
31.7 (2) | 28–33 |
|
RDW (%) n = 19 |
15.0 (3.6) | 12–15% |
|
Absolute lymphocyte count (103/µL) n = 18 |
0.6 (0.6) | 1.3–3.5 |
|
Absolute neutrophil count (106/µL) n = 19 |
7.3 (6.1) | 1.7–7.3 |
| Coagulation | ||
|
d-dimer (ng/mL) n = 17 |
2190 (4125) | ≤ 500 |
|
PT (s) n = 10 |
14.0 (3.6) | 12.1–15.0 |
|
PTT (s) n = 11 |
29 (11) | 25–38 |
|
INR n = 10 |
1.0 (0.4) | 2.0–3.0 |
| Chemistry | ||
|
Sodium (mmol/L) n = 21 |
137 (4) | 136–145 |
|
Potassium (mmol/L) n = 21 |
4.1 (0.3) | 3.5–5.1 |
|
BUN (mg/dL) n = 21 |
22 (26.5) |
M: 9–20 F: 7–17 |
|
Bicarbonate (mmol/L) n = 21 |
29 (11) | 21–30 |
|
Bilirubin (mg/dL) n = 19 |
0.6 (0.3) | 0.2–1.3 |
|
Creatinine (mg/dL) n = 21 |
1.04 (0.89) |
M: 0.66–1.25 F: 0.52–1.04 |
Data are n (%) or median (IQR).